Promises and perils of the FDA's over-the-counter naloxone reclassification

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00092-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsmi=267731162&_hsenc=p2ANqtz--yDnwHZ6DaR9BRTLkbgNFa5pthVLT4moJVDrPRfIoAIpOoekwtyzaq0cHS_tGtzHgSKWpG5UdMRUOyvg2-y8Lq1N452Q&utm_content=267653145&utm_source=hs_email